These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

177 related articles for article (PubMed ID: 19034707)

  • 21. Vasoactive intestinal peptide (VIP)/pituitary adenylate cyclase-activating peptide receptor subtypes in mouse calvarial osteoblasts: presence of VIP-2 receptors and differentiation-induced expression of VIP-1 receptors.
    Lundberg P; Lundgren I; Mukohyama H; Lehenkari PP; Horton MA; Lerner UH
    Endocrinology; 2001 Jan; 142(1):339-47. PubMed ID: 11145597
    [TBL] [Abstract][Full Text] [Related]  

  • 22. In memory of our teacher, Dr. Akira Arimura.
    Shioda S; Vaudry H; May V; Braas K; Reglodi D; Gozes I
    J Mol Neurosci; 2008 Nov; 36(1-3):3-7. PubMed ID: 18607775
    [No Abstract]   [Full Text] [Related]  

  • 23. Expression and function of vasoactive intestinal peptide, pituitary adenylate cyclase-activating polypeptide, and their receptors in the human adrenal gland.
    Mazzocchi G; Malendowicz LK; Rebuffat P; Gottardo L; Nussdorfer GG
    J Clin Endocrinol Metab; 2002 Jun; 87(6):2575-80. PubMed ID: 12050216
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Ventilatory and cardiovascular actions of centrally and peripherally administered trout pituitary adenylate cyclase-activating polypeptide (PACAP) and vasoactive intestinal peptide (VIP) in the unanaesthetized trout.
    Le Mével JC; Lancien F; Mimassi N; Conlon JM
    J Exp Biol; 2009 Dec; 212(Pt 23):3919-27. PubMed ID: 19915135
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Effects of pituitary adenylate cyclase-activating polypeptide and vasoactive intestinal polypeptide on food intake and locomotor activity in the goldfish, Carassius auratus.
    Matsuda K; Maruyama K; Nakamachi T; Miura T; Shioda S
    Ann N Y Acad Sci; 2006 Jul; 1070():417-21. PubMed ID: 16888202
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Vasoactive intestinal peptide and pituitary adenylate cyclase activating polypeptide stimulate interleukin-6 production in prostate cancer cells and prostatic epithelial cells.
    Nagakawa O; Junicho A; Akashi T; Koizumi K; Matsuda T; Fuse H; Saiki I
    Oncol Rep; 2005 Jun; 13(6):1217-21. PubMed ID: 15870945
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Receptors for pituitary adenylate cyclase-activating peptide in human liver.
    Guijarro LG; Rodriguez-Henche N; García-López E; Noguerales F; Dapena MA; Juarranz MG; Prieto JC
    J Clin Endocrinol Metab; 1995 Aug; 80(8):2451-7. PubMed ID: 7629241
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Characterization of ocular receptors for pituitary adenylate cyclase activating polypeptide (PACAP) and their coupling to adenylate cyclase.
    Nilsson SF; De Neef P; Robberecht P; Christophe J
    Exp Eye Res; 1994 Apr; 58(4):459-67. PubMed ID: 7925682
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Distribution of vasoactive intestinal peptide, pituitary adenylate cyclase-activating peptide, nitric oxide synthase, and their receptors in human and rat sphenopalatine ganglion.
    Csati A; Tajti J; Kuris A; Tuka B; Edvinsson L; Warfvinge K
    Neuroscience; 2012 Jan; 202():158-68. PubMed ID: 22108610
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Recognition of pituitary adenylate cyclase-activating polypeptide/vasoactive intestinal polypeptide (PACAP/VIP) hybrids and related peptides by rat brain membranes.
    Ando E; Nokihara K; Naruse S; Wray V
    Biomed Pept Proteins Nucleic Acids; 1996; 2(2):41-6. PubMed ID: 9346825
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Inhibitory effects of pituitary adenylate cyclase-activating polypeptide (PACAP) and vasoactive intestinal peptide (VIP) on food intake in the goldfish, Carassius auratus.
    Matsuda K; Maruyama K; Nakamachi T; Miura T; Uchiyama M; Shioda S
    Peptides; 2005 Sep; 26(9):1611-6. PubMed ID: 16112400
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Noncompensation in peptide/receptor gene expression and distinct behavioral phenotypes in VIP- and PACAP-deficient mice.
    Girard BA; Lelievre V; Braas KM; Razinia T; Vizzard MA; Ioffe Y; El Meskini R; Ronnett GV; Waschek JA; May V
    J Neurochem; 2006 Oct; 99(2):499-513. PubMed ID: 17029602
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Pituitary adenylate cyclase-activating polypeptide (PACAP) and PACAP-receptor type 1 expression in rat and human placenta.
    Scaldaferri ML; Modesti A; Palumbo C; Ulisse S; Fabbri A; Piccione E; Frajese G; Moretti C
    Endocrinology; 2000 Mar; 141(3):1158-67. PubMed ID: 10698193
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Vasoactive intestinal peptide and pituitary adenylate cyclase-activating polypeptide inhibit chemokine production in activated microglia.
    Delgado M; Jonakait GM; Ganea D
    Glia; 2002 Aug; 39(2):148-61. PubMed ID: 12112366
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Receptors for pituitary adenylate cyclase activating peptides in human pituitary adenomas.
    Robberecht P; Vertongen P; Velkeniers B; de Neef P; Vergani P; Raftopoulos C; Brotchi J; Hooghe-Peters EL; Christophe J
    J Clin Endocrinol Metab; 1993 Nov; 77(5):1235-9. PubMed ID: 8077316
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Regulation of feeding behavior by pituitary adenylate cyclase-activating polypeptide (PACAP) and vasoactive intestinal polypeptide (VIP) in vertebrates.
    Matsuda K; Maruyama K
    Peptides; 2007 Sep; 28(9):1761-6. PubMed ID: 17466413
    [TBL] [Abstract][Full Text] [Related]  

  • 37. PACAP-38 but not VIP induces release of CGRP from trigeminal nucleus caudalis via a receptor distinct from the PAC1 receptor.
    Jansen-Olesen I; Baun M; Amrutkar DV; Ramachandran R; Christophersen DV; Olesen J
    Neuropeptides; 2014 Apr; 48(2):53-64. PubMed ID: 24508136
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Characterization, expression, and functional activity of pituitary adenylate cyclase-activating polypeptide and its receptors in human granulosa-luteal cells.
    Morelli MB; Barberi M; Gambardella A; Borini A; Cecconi S; Coticchio G; Canipari R
    J Clin Endocrinol Metab; 2008 Dec; 93(12):4924-32. PubMed ID: 18782879
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Early changes in pituitary adenylate cyclase-activating peptide, vasoactive intestinal peptide and related receptors expression in retina of streptozotocin-induced diabetic rats.
    Giunta S; Castorina A; Bucolo C; Magro G; Drago F; D'Agata V
    Peptides; 2012 Sep; 37(1):32-9. PubMed ID: 22721946
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Vasoactive intestinal peptide and pituitary adenylate cyclase-activating polypeptide: players in innate and adaptive immunity.
    Ganea D; Rodriguez R; Delgado M
    Cell Mol Biol (Noisy-le-grand); 2003 Mar; 49(2):127-42. PubMed ID: 12887096
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.